Prolactin Receptor and Head and Neck Cancer
Author Information
Author(s): Bauernhofer T, Pichler M, Wieckowski E, Stanson J, Aigelsreiter A, Griesbacher A, Groselj-Strele A, Linecker A, Samonigg H, Langner C, Whiteside T L
Primary Institution: Medical University of Graz
Hypothesis
Could the prolactin receptor be a potential drug target in squamous cell carcinomas of the head and neck?
Conclusion
High levels of prolactin receptor expression are associated with poorer overall survival in patients with squamous cell carcinoma of the head and neck.
Supporting Evidence
- 95% of tumors showed immunoreactivity for the prolactin receptor.
- High prolactin receptor expression was linked to a 3.7 times higher risk of poor overall survival.
- Patients with high prolactin receptor expression had a 75% recurrence rate compared to 38% in the low expression group.
Takeaway
This study found that a lot of head and neck cancer patients have a protein called the prolactin receptor, and having more of it means they might not live as long.
Methodology
The study evaluated prolactin receptor expression in cancer cell lines and tissue samples from patients, using immunohistochemistry and statistical analysis to correlate expression with clinical outcomes.
Limitations
The study had a relatively small number of patients in the low expression group, which may limit the generalizability of the findings.
Participant Demographics
{"total_patients":89,"male":67,"female":22,"median_age":{"male":56,"female":65}}
Statistical Information
P-Value
0.029
Confidence Interval
95% CI: 1.14–12.01
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website